Kiora Pharmaceuticals (KPRX) Cash from Operations (2014 - 2026)
Kiora Pharmaceuticals' (KPRX) quarterly Cash from Operations came in at 3161332.0 in Q1 2026, down 16.9% YoY from 3804459.16 in Q1 2025, and down 44.98% on a QoQ basis from 2180455.0 in Q4 2025.
Kiora Pharmaceuticals (KPRX) Cash from Operations (2014 - 2026) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 13 years of Cash from Operations data on file, last reported at 3161332.0 in Q1 2026.
- Quarterly Cash from Operations fell 16.9% year-over-year to 3161332.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 10418309.0 (down 34.08% YoY) and the FY2025 annual result came in at 9961176.0, down 216.38% from the prior year.
- Cash from Operations slipped to 3161332.0 in Q1 2026, from 2180455.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 13624855.0 in Q1 2024 to a low of 3803434.0 in Q2 2025.
- A 5-year average of 1444028.06 and a median of 2521097.0 in 2023 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2024 — Cash from Operations soared 543.87% — and 2025, when it sank 238.37%.
- Tracing KPRX's Cash from Operations over 5 years: stood at 2129000.0 in 2022, then dropped by 21.25% to 2581341.0 in 2023, then climbed by 12.74% to 2252358.0 in 2024, then rose by 3.19% to 2180455.0 in 2025, then tumbled by 44.98% to 3161332.0 in 2026.
- The last three Cash from Operations figures came in at 3161332.0 (Q1 2026), 2180455.0 (Q4 2025), and 1273088.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Kiora Pharmaceuticals | 15.64 Mn | 15.64 Mn | - | -1.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.89 Mn |
| Jun 30, 2026 | -1.89 Mn |
| Mar 31, 2026 | -3.16 Mn |
| Mar 31, 2026 | -3.16 Mn |
| Dec 31, 2025 | -2.18 Mn |
| Dec 31, 2025 | -2.18 Mn |
| Sep 30, 2025 | -1.27 Mn |
| Sep 30, 2025 | -1.27 Mn |
| Jun 30, 2025 | -3.80 Mn |
| Jun 30, 2025 | -3.80 Mn |
| Mar 31, 2025 | -2.70 Mn |
| Mar 31, 2025 | -2.70 Mn |
| Dec 31, 2024 | -2.25 Mn |
| Dec 31, 2024 | -2.25 Mn |
| Sep 30, 2024 | 920,057.00 |
| Sep 30, 2024 | 920,057.00 |
| Jun 30, 2024 | -3.73 Mn |
| Jun 30, 2024 | -3.73 Mn |
| Mar 31, 2024 | 13.62 Mn |
| Mar 31, 2024 | 13.62 Mn |